Overview

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin degludec, insulin aspart drug combination
Insulin Detemir
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting